Loading people...
Kevin Gillis is a Partner at Third Rock Ventures, a leading life sciences venture firm. He is instrumental in the creation and operational development of innovative biotechnology companies, leveraging his deep financial and operational expertise.
As part of Third Rock Ventures, Kevin Gillis focuses on building and supporting early-stage life science companies, particularly those involved in drug discovery, therapeutic development, and novel healthcare solutions. His expertise often centers on the financial and operational strategies for these ventures.
Kevin Gillis works as a Partner at Third Rock Ventures, an organization dedicated to founding, building, and investing in groundbreaking life science companies, primarily in the biotechnology and healthcare sectors.
Kevin Gillis is a distinguished Partner at Third Rock Ventures, a leading venture capital firm renowned for its unique approach to founding and building transformative life science companies. At Third Rock Ventures, Kevin is instrumental in the firm's core mission of company creation, leveraging his extensive background in finance and operations to guide nascent biotechnology ventures from concept to market leadership. His role involves not just identifying promising scientific breakthroughs but actively participating in the strategic and operational build-out of these companies.
His investment focus at Third Rock Ventures is squarely within the life sciences, encompassing areas such as novel drug discovery, therapeutic platform development, and innovative healthcare solutions. Kevin's contributions are critical in shaping the financial architecture and operational strategies for these early-stage companies, ensuring they are well-positioned for growth and success in a complex industry. He helps navigate the intricate landscape of biotech development, from securing initial funding to scaling operations and preparing for clinical trials.
Before joining Third Rock Ventures in 2014, Kevin Gillis built an impressive career marked by significant leadership roles in the biotechnology sector. He served as Chief Financial Officer for several prominent biotech companies, both public and private. His tenure included key positions at Affymax, Inc., a publicly traded biopharmaceutical company, and InterMune, Inc., which was later acquired by Roche. He also held CFO roles at Peninsula Pharmaceuticals, Inc., acquired by Johnson & Johnson, and Tularik Inc., which was acquired by Amgen. This rich operational and financial background provides him with invaluable insights into the challenges and opportunities faced by biotech startups, making him a highly effective company builder and strategic advisor.
While Third Rock Ventures operates as a firm that creates companies rather than individual partners making traditional 'investments,' Kevin Gillis's expertise has been vital in the establishment and growth of numerous innovative companies within the Third Rock portfolio. His operational acumen and financial stewardship have been critical in helping these ventures advance groundbreaking science into potential new medicines and therapies, ultimately aiming to make a profound impact on patient lives.
Kevin Gillis is a Partner and Chief Operating Officer at Third Rock Ventures, a biotechnology venture capital firm based in Boston, Massachusetts. Joining the firm in 2008, he oversees non-investment activities including finance, legal, communications, and fundraising, helping manage operations for an entity that has raised over $3.8 billion across multiple funds. Prior to this role, he served as Chief Financial Officer at Coley Pharmaceutical Group, where he helped lead the company through its $164 million acquisition by Pfizer. His earlier career includes financial leadership positions at Flagship Pioneering and PricewaterhouseCoopers, following his undergraduate education at Brandeis University and his MBA from Bentley University. Today, his operational leadership supports a portfolio of life sciences companies, including insitro and Syremis Therapeutics, as he focuses on scaling healthcare ventures developing preventive medicines and novel disease treatments.
